AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02042092 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRA
Study NCT00787475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Health worker
Description: Community Health workers with at least 4 home visits, 8 phone calls, and 10 group visits.
Study NCT01020578 — intervention group
Intervention type: OTHER
Intervention: Plasma kinetic study
Description: This study is done with the injection of an artificial lipid nanoemulsion doubly labeled with 14C-cholesteryl oleate and 3H-cholesterol, with a total radioactivity injection dose of 0.03mSV. Blood samples collected in a pre established period of time in 24 hours.
Study NCT01631916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroid
Description: Dexamethasone 0.6 mg/kg/day or Methylprednisone 1 mg/kg/day
Study NCT00651599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)
Description: Treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval.
Study NCT00651599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval.
Study NCT01697826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ClinSupV3 -soft gelatin capsule
Description: 3 day treatment with intravaginal formulation containing 100mg Clindamycin and 200mg clotrimazole
Study NCT01697826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ClinSupV3ER- Extended release tablet
Description: 3 day treatment with intravaginal formulation containing 100mg Clindamycin and 200mg Clotrimazole
Study NCT02404298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIg
Study NCT03178591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vildagliptin
Study NCT03178591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Study NCT02796495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Operation of hand prosthesis with direct nerve stimulation
Description: Four TIME-4H electrodes will be implanted in the median and ulnar nerves of the amputees. The electrodes will be connected with the STIMEP electrical multichannel stimulator. The stimulator will be connected with one of the two sensorized hand prosthesis. Afferent and efferent signals will be elaborated and integrated by the ODROID software.~The amputees will be able to control the prosthetic hand movement and receive a sensory feedback from the prosthesis sensors.~The use of the prosthesis during different tasks will be considered the intervention.
Study NCT02040038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LIVE
Description: 3-D Virtual Environment for DSMT/S
Study NCT02040038 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Website
Description: 2-D Website participation for DSMT/S
Study NCT02147964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline
Description: Acyline 300 ug/kg SQ injections every 2-weeks for 4 months \[all subjects\]
Study NCT02147964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Description: Dutasteride 2.5 mg (day 1) followed by 0.5 mg daily for 4 months
Study NCT02147964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: ketoconazole 400 mg PO daily for 4 months
Study NCT02147964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCG
Description: HCG 60 IU injection Subcutaneously, every other day for 4 months
Study NCT02147964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo dutasteride
Description: placebo oral dutasteride PO daily for 4 months
Study NCT02147964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo ketoconazole
Description: placebo ketoconazole daily for 4 months
Study NCT03008759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dentifrice 100% Nano-F
Description: Use of few of dentifrice 100% Nanoencapsulated Fluoride on brushing for one week, twice day.
Study NCT03008759 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dentifrice 100% Nano-F
Description: Use of few of dentifrice 100% Nanoencapsulated Fluoride on brushing for one week, twice day.
Study NCT03008759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dentifrice 50% Nano-F
Description: Use of few of dentifrice 50% Nanoencapsulated Fluoride on brushing for one week, twice day.
Study NCT03008759 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dentifrice 50% Nano-F
Description: Use of few of dentifrice 50% Nanoencapsulated Fluoride on brushing for one week, twice day.
Study NCT03008759 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dentifrice standard
Description: Use of few of dentifrice on brushing for one week, twice day. It's for the positive control of fluorid
Study NCT03008759 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dentifrice standard
Description: Use of few of dentifrice on brushing for one week, twice day. It's for the positive control of fluorid
Study NCT02170909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS low dose
Study NCT02170909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS medium dose
Study NCT02170909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS high dose
Study NCT03051594 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fluorescent camera
Description: used too detect residual caries depending on the bacterial byproducts.
Study NCT03051594 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: caries detector dye
Description: dye used to detect the residual caries.
Study NCT03051594 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: visual tactile assessment
Description: method usually used to detect the residual caries.
Study NCT01831817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice
Description: Calcium sodium phosphosilicate dentifrice (5% w/w) and 1500 ppm F as sodium monofluorophosphate
Study NCT01831817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice
Description: No calcium sodium phosphosilicate and 1500 ppm F as sodium monofluorophosphate
Study NCT01831817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium monofluorophosphate dentifrice
Description: Sodium monofluorophospate dentifrice (1000 ppm F)
Study NCT01831817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Fluoride dentifrice
Description: Dentifrice containing 1100ppm F as sodium fluoride
Study NCT00428207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart versus Insulin Lispro
Description: Subjects will be randomly assigned to insulin aspart versus insulin lispro via random number generation. Half of the patients will begin with insulin aspart, and then will be crossed over to insulin lispro. The insulin sequence will be reversed for the other half of the patients.
Study NCT00428207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro versus Insulin Aspart
Description: Subjects will be randomly assigned to insulin lispro versus insulin aspart via random number generation. Half of the patients will begin with insulin lispro, and then will be crossed over to insulin aspart. The insulin sequence will be reversed for the other half of the patients.
Study NCT00946673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Orally up to 400 mg
Study NCT00946673 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Single fraction stereotactic radiotherapy - Standard of Care
Study NCT01294163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon
Description: Inhaled xenon, maximal inspired concentration of 65%.
Study NCT01294163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Inhaled sevoflurane, maximal inspired concentration of 1.8%.
Study NCT01294163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Hourly dose of 2-4 mg/kg
Study NCT05749120 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Recipient vessel selected for microanastomosis
Description: Free tissue flaps harvesting and microanastomosis were performed by the same surgeon and in a similar way in both group. Postoperative course, and complications were recorded and analyzed.
Study NCT05749120 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Recipient vessel selected for microanastomosis
Description: Free tissue flaps harvesting and microanastomosis were performed by the same surgeon and in a similar way in both group. Postoperative course, and complications were recorded and analyzed.
Study NCT05011799 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cancer Educational Materials
Description: Receive prostate cancer educational materials
Study NCT05011799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05011799 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05011799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Attend peer-led education sessions
Study NCT02737384 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Depletion in CD45RA graft donor
Description: Experimental treatment: negative fraction after CD34+ selection from PBSC graft is depleted of naïve CD45RA+ cells. this fraction is reinjected to the recipient and is the experimental product.~Conditioning regimen:~Up-front ATG from D-14 toD-11 Busulphan IV from D-8 to -5 Fludarabine from D-7 to D-4 Thiothepa D-3 to D-2~Graft: CD34+ cells positively selected cells from PBSC of the donor~Post transplant immunosuppression: ciclosporin started at D-1 to D+100
Study NCT04665531 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Catheter
Description: Patients in the experimental group will receive the Erector Spinae Catheter with an initial bolus ob 20ml 0,5% levobupivacaine prior the surgery and will be administered local anesthetics for 48 hours post-operatively.
Study NCT04665531 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal block
Description: Patients in the comparative group will receive standard treatment, i.e. the multi-level intercostal block with 20ml 0,5% levobupivacaine administered at the end of the surgery by the surgeon.
Study NCT04665531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% Injectable Solution
Description: Patients in the experimental group will receive Ropivacaine 0,2% continous infusion of 5ml/h with boluses 15ml/4h by the Erector Spinae Catheter for 48 hours post-operatively.
Study NCT02155530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40mg
Description: homogenous neointimal pattern at baseline OCT and randomized to atorvastatin 40 mg group
Study NCT02155530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pravastatin 20 mg
Description: Intervention description : homogenous neointimal pattern at baseline OCT and randomized to pravastatin 20 mg group
Study NCT00712582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide, carboplatin, ifosfamide
Description: Patients in consolidation A will receive three drugs in a regimen called ICE. You will have 3 cycles. Each new cycle begins 2 to 3 weeks after the last one.
Study NCT00712582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, Ifosfamide, Etoposide, Carboplatin
Description: It consists of four drugs in a regimen called augmented RICE (augRICE). It is given every 3 weeks for 2 cycles.
Study NCT00712582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine
Description: It consists of four drugs in a regimen called augRICE. It is given every 3 weeks for 2 cycles. After the rituximab on day 3, you will then be admitted to the hospital for 2 to 3 nights.~Part 2: Stem Cell Collection, Part 3: High dose chemoradiotherapy and stem cell transplant. Your doctor may want you to get radiation therapy. If so, it will start 2 weeks before the highdose chemotherapy. This regimen is called CBV-N chemotherapy. It is given by vein in the hospital.
Study NCT01326832 — intervention group
Intervention type: DEVICE
Intervention: Primoris
Description: Total hip arthroplasty with the new Primoris femoral component
Study NCT03491995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Classic treatment
Description: Omeprazole, amoxycillin, clarithromycin
Study NCT04349488 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Anodal Transcranial Direct Current Stimulation
Description: Subjects received a micro-current through their scalp to induce cortical and subcortical changes
Study NCT04349488 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal Transcranial Direct Current Stimulation
Description: Subjects received a micro-current through their scalp to induce cortical and subcortical changes
Study NCT00536107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: 250 mg oral
Study NCT00536107 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CT or MRI
Description: performed at screening and every 6 weeks
Study NCT00536107 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT or MRI
Description: performed at screening and every 6 weeks
Study NCT00536107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 60mg/m2 intravenous infusion
Study NCT02047357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Learning Through Play Plus
Description: Learning Through Play (LTP) Plus is a low-literacy, sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Thinking Healthy Program (THP) which adopts 'here and now' problem-solving approach. THP uses cognitive behavior therapy (CBT) techniques of active listening, changing negative thinking, and collaboration with the family.
Study NCT02420691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02420691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02420691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Given PO
Study NCT04390477 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Oral daily capsule containing probiotic strains with maltodextrin as excipient, administrated for 30 days.
Study NCT03797209 — intervention group
Intervention type: DEVICE
Intervention: EUS-guided fistulization AXIOS
Description: By using a convex type ultrasonic endoscope to form a fistula by gastrointestinal puncture, to perform various drainage.
Study NCT00870896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Each subject will then receive Spiriva 18 ug/day for a total of 4 weeks. Each subject will be instructed by the PI on the proper use of the Spiriva inhaler and demonstrate the ability to properly perform the inhalation technique prior to leaving the laboratory. The patient will receive their first dose in the laboratory under the direct supervision of one of the investigators. In addition, subjects will be requested to take their Spiriva inhalation treatment the same time each day.
Study NCT06418919 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation treatment
Description: RFA is used to ablate the entire thyroid gland
Study NCT04584736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Livalo, Ezetrol
Description: Pitavastatin+Ezetimibe Pitavastatin
Study NCT04584736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Livalo, Ezetrol
Description: Pitavastatin+Ezetimibe Pitavastatin
Study NCT02447601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEX168
Description: 200µg,injected subcutaneously,once a week.
Study NCT02447601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 40mg,oral,two times
Study NCT02771288 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Bioresorbable Vascular Scaffold
Study NCT03655314 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NEWT
Description: The Newborn Weight Tool (NEWT) is publicly available at www.newbornweight.org. For this intervention, NEWT will be embedded into the electronic medical record along with a flag for weight loss greater than or equal to the 75th centile of birth weight.
Study NCT03655314 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: The electronic medical record will display the weight only as weight in grams and percent weight lost from birth weight.
Study NCT01107197 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enriched nutrition formula
Description: oral formula enriched in arginine, zinc and antioxidant oligoelements
Study NCT01107197 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control formula
Description: Isonitrogenous isocaloric oral formula
Study NCT02246114 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: piCO+ Smokerlyzer® monitor
Study NCT02246114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text messages
Study NCT03636347 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: twice daily administration
Study NCT03636347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alvelestat oral tablet - dose 1
Description: twice daily administration
Study NCT03636347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alvelestat oral tablet - dose 2
Description: twice daily administration
Study NCT05880927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Patients receive pyrotinib 400mg/day for half or one year
Study NCT00721734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib was administered intravenously (IV) at a rate of approximately 10 mL/minute.
Study NCT04098224 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smART+ System
Description: Utilizing the smART+ System to provide feeding optimization to the patient
Study NCT02749643 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile feedback system
Study NCT00761267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Description: Day 1: loading dose of 3 mg/kg (not to exceed 200 mg) Day 2 onwards: maintain a dose of 1.5 mg/kg (not to exceed 100 mg). Minimum total treatment duration is 14 days. Minimum IV anidulafungin treatment duration is 10 days for subjects with microbiologically confirmed ICC and 5 days for subjects at risk of candidiasis; followed by oral fluconazole 6-12 mg/kg/day (not to exceed 800mg/day).~Maximum treatment duration with anidulafungin is 35 days.
Study NCT00761267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Subjects may be switched to oral fluconazole \[6-12 mg/kg/day (not to exceed 800mg/day\] provided they meet specified criteria. Maximum total treatment duration is 49 days.
Study NCT02161354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTC-510 capsules
Description: Subjects will be randomized to one of 3 groups and NTC-510 will be given as a single oral dose of 2.0 mg, a split dose of 2.0 mg followed by 2.0 mg an hour later, or 6.0 mg for acute pain relief (PR) following third molar extraction.
Study NCT02161354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Capsules
Description: Subjects will be randomized to one of 3 groups and placebo capsules will be given as a single oral dose of for acute dental pain following third molar extraction.
Study NCT02161354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTC-510A Capsules
Description: Subjects will be randomized to one of 3 groups where NTC-510A or placebo will be given as a single oral dose of 2.0, 4.0, or 6 mg for acute pain relief (PR) following third molar extraction
Study NCT03150758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 10Hz + 100 micro-seconds
Description: 10Hz Electrical Stimulation with a pulse width of 100 micro-seconds
Study NCT03150758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 10Hz + 200 micro-seconds
Description: 10Hz Electrical Stimulation with a pulse width of 200 micro-seconds
Study NCT03150758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7Hz + 100 micro-seconds
Description: 7Hz Electrical Stimulation with a pulse width of 100 micro-seconds